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pleted Patient Record Forms (PRFs); pts self-reported data including EQ-5D and the 
Work Productivity and Activity Impairment Index for SLE (WPAI-Lupus) in Patient 
Self-Completion Records (PSCs). Pt eligibility was determined by physicians; disease 
activity and severity were based on physician assessment. Data across countries 
were pooled. Results: Data were collected from rheumatologists in the USA (n= 97), 
France (n= 37) and Germany (n= 35), including PRFs (550/200/207, respectively) and 
PSCs (303/109/149, respectively). Physician assessment of disease severity was pre-
dominantly based on affected organs and symptoms (45% and 35% of rheumatolo-
gists, respectively); 15% based severity on test results/clinical assessments. No disease 
activity index was widely used, 58% used their own assessment. Physician assessment 
of severity was imperfectly correlated with control of disease activity (activity con-
trolled in 56.1% of “moderate-to-severe” pts, uncontrolled in 6.1% of “mild” pts). Pts 
with “moderate-to-severe” severity presented with greater severity and organ involve-
ment, and a higher proportion experienced flares per 12-month period than “mild” 
pts (78.4% vs 52.6%). “Moderate-to-severe” severity was associated with a greater 
impact on HRQoL (EQ-5D: 0.72 vs 0.86; WPAI: 35.0 vs 16.3) than “mild” disease. Fewer 
“moderate-to-severe” pts were employed (full-time employment: 35.8% vs 48.8%), 
and a higher proportion required a care provider (6.6% vs 3.3%). ConClusions: SLE 
severity is not consistently assessed or defined in clinical practice: measures used in 
clinical trials are not routinely adopted in daily practice, whilst organ involvement 
and symptoms are central to physician assessment of severity. Correlation between 
severity and control of disease activity is imperfect. “Moderate-to-severe” severity is 
associated with a greater burden than “mild” disease.
PSY5
EffEctivEnESS of HEavY-LigHt cHain QuantitativE tESt:  
a SYStEmatic REviEw
Kim J.H., Shin H.W., Lee M.
National evidence-based healthcare collaborating agency, Seoul, South Korea
objeCtives: Heavy-light chain (HLC) quantitative test can identity and quan-
tify the heavy and light chain of each immunoglobulin class. The purpose of this 
study was to evaluate the effectiveness of HLC quantitative test. Methods: To 
evaluate the effectiveness of HLC quantitative test, systemic literature review using 
Ovid-MEDLINE, EMBASE, Cochrane library and eight domestic databases including 
KoreaMED had performed until October 10th, 2013. We included five cohort studies 
and one diagnostic evaluation study in the final evaluation. Two reviewers inde-
pendently assessed the quality of included studies and extracted data on study. 
The qualities of these studies were assessed according to Scottish Intercollegiate 
Guidelines Network (SIGN) tool. Results: The correlation between HLC quanti-
tative test with previous tests was evaluated in one study which patients with 
increased monoclonal IgA were enrolled, and the correlation coefficient with com-
parator tests was reported as 0.94 in that study. Clinical significance of quantitative 
HLC test for predicting prognosis was also reported in five cohort studies. Survival 
rate in patients with higher HLC ratio was significantly lower, and the increased 
IgA κ /λ ratio or IgM κ /λ ratio was significantly correlated with higher survival rate 
in patients with monoclonal gammaglobulinemia. The body of evidence as a whole 
suggests a Grade C for HLC quantitative test. ConClusions: HLC quantitative test 
is safe and effective test that can quantitatively measure the identified immuno-
globulin type and predict the prognosis of patients with monoclonal gammopathy.
PSY6
DiSaPPEaRancE of B-SYmPtomS in comoRBiD PatiEntS REcEiving fiRSt-
LinE oBinutuzumaB (ga101) -cHLoRamBuciL (g-cLB) oR RituximaB-
cHLoRamBuciL (R-cLB) foR cHRonic LYmPHocYtic LEukEmia (cLL)
Wenk Andres S.1, Becker U.2, Klawitter S.1, Wiesner C.3, Bernhardt A.2
1Roche Pharma aG, Grenzach-Wyhlen, Germany, 2F. hoffmann-La Roche Ltd., Basel, Switzerland, 
3Genentech Inc., South San Francisco, ca, USa
objeCtives: The CLL11 study (stage 2, NCT02053610; sponsored by F. Hoffmann-La 
Roche, Basel, Switzerland), compared G-Clb with R-Clb in 663 patients with previ-
ously untreated CLL and comorbidities. We compared the presence, disappearance 
and duration of absence of B-symptoms (fever, night sweats and weight loss) for 
G-Clb with R-Clb in CLL11. Methods: Patients were randomised to receive six 
28-day (D) cycles (C) of G-Clb (N= 333) or R-Clb (N= 330; G: 1000 mg D1, 8 and 15 C1, 
D1C2–6; R: 375 mg/m2 D1C1, 500 mg/m2 D1C2–6; Clb: 0.5 mg/kg D1 and 15 each 
cycle). B-symptoms were assessed by a physician at baseline, D1C1, D8C1, D1 of 
each subsequent cycle, 28 days after last study drug and every 3–6 months dur-
ing follow-up for progression-free survival. The data cut-off for this analysis was 
9thMay 2013. Results: At baseline, 260 patients had B-symptoms (n= 126, G-Clb; 
n= 134, R-Clb). During the treatment period, B-symptoms disappeared in 107 (85%) 
and 124 (93%) patients who received G-Clb and R-Clb, respectively (relative risk 
[RR]: 0.92, 95% confidence interval [CI]: 0.84–1.00; p= 0.0554). Median time to first 
disappearance of all B-symptoms was 32.0 days for G-Clb and 35.0 days for R-Clb 
(hazard ratio [HR]: 1.24,95% CI: 0.96–1.61; p= 0.103). At end of treatment, 96 (76%) 
and 108 (81%) patients who received G-Clb and R-Clb, respectively, were B-symptom 
free (RR: 0.95, 95% CI: 0.83–1.07; p= 0.3899). In patients whose B-symptoms disap-
peared, the 25% quartile for duration of absence of B-symptoms (median not 
reached) was 16.4 months for G-Clb and 10.4 months for R-Clb (HR: 0.59, 95% CI: 
0.36–0.97; p= 0.0387). ConClusions: There was no clinically meaningful difference 
in B-symptom freeness at end of treatment, however the absence of B-symptoms 
was prolonged by 6 months for G-Clb versus R-Clb.
PSY7
comPaRiSon of DiSEaSE StatuS anD outcomES of PatiEntS witH 
ankYLoSing SPonDYLitiS (aS) REcEiving aDaLimumaB oR EtanERcEPt 
monotHERaPY in EuRoPE
Narayanan S.1, Lu Y.2, Hutchings R.2, Baynton E.2
1Ipsos healthcare, columbia, MD, USa, 2Ipsos healthcare, London, UK
objeCtives: To compare the disease status and outcomes of patients with AS 
receiving adalimumab and etanercept monotherapy in Europe. Methods: A multi-
D) CAT-Health scores of -1.2412 (1.6065) vs -0.0119 (1.3495) (p< 0.001). Patients tak-
ing opioids also showed worse scores: -1.1009 (1.9349) vs -0.3288 (1.4169) (p= 0.037). 
Differences on HRQoL according to antidepressant drugs were not statistically sig-
nificant. Episodes of pain during dialysis were concentrated in 24 patients who had 
6 or more painful sessions. These patients were taking analgesics more frequently 
(86.4% vs 36.9%; p< 0.001) and showed worse CAT-Health score: -1.5391 (1.6348) vs 
-0.3243 (1.4981) (p= 0.005). ConClusions: Pain during haemodialysis sessions is 
very common and requires the frequent use of analgesics, having a negative impact 
on patients’ HRQoL.
PSY2
cLinicaL utiLitY of tHE coLLEct ScaLE to aSSESS comoRBiDitiES in 
PatiEntS witH cHRonic LYmPHocYtic LEukEmia
De La Serna J.1, Carbonell F.2, Giraldo P.3, Lopez A.4, González I.5, García C.5, Orofino J.5,  
Roset M.6, Perulero N.6, Rios E7
1hospital Universitario 12 de Octubre, Madrid, Spain, 2consorci hospital General Universitari 
Valencia, Valencia, Spain, 3hospital Universitario Miguel Servet, Zaragoza, Spain, 4hospital 
Universitari Valle d’hebron, Barcelona, Spain, 5Roche Pharma, Madrid, Spain, 6IMS health, 
Barcelona, Spain, 7hospital Virgen de Valme, Sevilla, Spain
objeCtives: COLLECT scale assesses comorbidities in patients with Chronic 
Lymphocytic Leukemia (CLL). Validation of COLLECT was a secondary objective 
of the MABERYC non-interventional study. The aim is to assess the clinical util-
ity and the validity of COLLECT to guide treatment regimen prescribed to CLL 
patients. Methods: MABERYC study included patients with CLL, being or not previ-
ously treated, initiating treatment with Rituximab+chemotherapy. COLLECT was 
administered at baseline and 12 months following treatment finalization. Treatment 
response (TR) and safety was also assessed in the last visit. COLLECT categorizes 
comorbidity in low (0-3), moderate (4-7) and high (> 7). Changes in COLLECT were 
categorized in improvement (reduction≥ 2), without changes (variation< 2) and 
worsening (increase≥ 2). Results: MABERYC included 218 patients, 179 completed 
COLLECT at baseline. Patients had a mean age of 67.5 years, 73% were male, 53% 
were naïve, 37% had moderate comorbidity and 27% high comorbidity. At baseline, 
42% of patients initiated treatment with Rituximab-Fludarabine-Ciclofosfamide 
(RFC), 30% with Rituximab-Bendamustine (RB), 18% with Rituximab-Clorambucile 
(RC) and 10% other patterns. Mean COLLECT score was higher in older patient, 
higher ECOG, previously treated (5.2 vs 4.2) and those receiving less aggressive treat-
ments (5.8 RC, 5.4 RB, 3.6 RFC). Changes in COLLECT were analysed in 134 patients. 
CR could be associated to improvement in comorbidity. Complete remission was 
reached by 53% of patients with COLLECT improvement, 47% without changes, and 
32% worsening. Number of adverse events (AEs) treatment related tend to be higher 
in patient with lower comorbidity (1.6 vs 0.9), using more aggressive treatments. 
Total number of AEs (related or not to treatment) tend to be higher in patients with 
higher comorbidity (7.8 vs 5.8). ConClusions: COLLECT scale assess comorbid-
ity which is related with patients’ profile, treatment regiment prescribed, CR and 
AEs. COLLECT could assist decision-making on the intensity of the chemotherapy 
regimen to prescribe.
PSY3
imPact of BioLogicS uSE on DEPRESSion anD anxiEtY fREQuEncY anD 
HEaLtH caRE RESouRcE utiLization in PSoRiaSiS: an anaLYSiS uSing tHE 
QuEBEc PRovinciaL DRug REimBuRSEmEnt PRogRam DataBaSE
Lachaine J.1, Lambert-Obry V.1, Gaumond S.2, Desjardins O.3
1University of Montreal, Montreal, Qc, canada, 2abbVie canada, Saint-Laurent, Qc, canada, 
3abbVie canada, St-Laurent, Qc, canada
objeCtives: Psoriasis is a chronic inflammatory disease of the skin that cannot 
be cured. For patients with active moderate to severe psoriasis, biologics use is 
associated with an improvement in patients’ quality of life especially by reducing 
prevalence of psychological disorders. The objective of this study was to assess 
the impact of biologics use on depression and anxiety frequency and the number 
of medical visits. Methods: A retrospective study of the Quebec provincial drug 
reimbursement program (RAMQ) database was conducted using a randomly selected 
group of patients who have received at least one diagnosis of psoriasis between 
January 1st, 2007 and June 30th, 2012. To assess the impact of biologics use, time series 
analyses were performed. Time series analyses evaluate changes in the slope of a 
trend pre- and post-intervention, herein defined as biologics initiation. Trends in 
depression and anxiety frequency and medical visits frequency were compared for 
each year for a 5-year period before and after biologics initiation to assess the dif-
ferences in slopes. Results: A total of 43,400 patients with psoriasis were included 
in the study (mean age= 54.6 [SD= 21.9] years, 53.7% females), of which 1,108 (2.6%) 
used a biologic agent. For patients who needed to be treated with biologics, the 
rates of change in the depression and anxiety prevalence increased by 3.4% and by 
4.2% per year prior to biologics initiation respectively. After biologics initiation, the 
trends were still increasing, but at a statistically lower rate of 2.5% (p= 0.028) and of 
2.4% (p= 0.012) per year. Medical visits per patient increased during the 5-year period 
before biologics initiation. Visits frequency has reduced during the 5-year period 
after biologics initiation with a trend decreasing annually (p= 0.002). ConClusions: 
The present analysis illustrates that biologics use reduces the increase in depression 
and anxiety frequency and decreases the number of medical visits.
PSY4
a REaL-woRLD cHaRactERization of PatiEntS witH “moDERatE-to-
SEvERE” SYStEmic LuPuS ERYtHEmatoSuS
Strand V.1, Johnson J.2, Vandeloo C.3, Galateanu C.3, Lobosco S.2
1Biopharmaceutical consultant, Portola Valley, ca, USa, 2adelphi Real World Ltd, Macclesfield, 
UK, 3UcB Pharma, Brussels, Belgium
objeCtives: To characterize the patient (pt) group classified by physicians as hav-
ing “moderate-to-severe” systemic lupus erythematosus (SLE) disease severity, and 
assess disease burden. Methods: Data were extracted from the Adelphi 2013 Lupus 
Disease-Specific Program, a multinational survey of clinical practice. Physicians com-
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erase 45U/kg). Non significative differences implies overlapped confidence intervals 
for the three therapies in all the efficacy endpoints. ConClusions: This analysis 
suggests a comparable effect of the velaglucerase and taliglucerase on platelet count 
increase, as well as a comparable effect of the three enzymes approved for Gaucher 
disease on Hemoglobin concentration increase, Liver and Spleen volume reduction.
PSY10
tHE oncoLogY Pain tREatmEnt cLinicaL StuDiES QuaLitY aSSESSmEnt
Giermaziak W.1, Faluta T.2, Bondaryk Z.1, Markowska A.1, Deszcz M.3
1Main Medical Library, Warsaw, Poland, 2Military Institite of Medicine, Warsaw, Poland, 3Medical 
University of Warsaw, Warsaw, Poland
objeCtives: Opioids have been extensively used in the treatment of oncological 
pain for many years. Due to various therapeutic doses and imprecise measure-
ments of the reduction of pain, it is difficult to make meta-analysis. There are 
only a few precise systematic reviews assessing efficacy of pain medicines (espe-
cially meta-analysis). The study goal was to assess the quality of published data 
of oncological pain treatment and create a meta-analysis when it is possible. It 
has been led in the context of a limited amount of meta-analysis for the opioid 
preparations’ use. Methods: Opioids have been extensively used in the treat-
ment of oncological pain for many years. Due to various therapeutic doses and 
imprecise measurements of the reduction of pain, it is difficult to make meta-
analysis. There are only a few precise systematic reviews assessing efficacy of pain 
medicines (especially meta-analysis). The study goal was to assess the quality of 
published data of oncological pain treatment and create a meta-analysis when 
it is possible. It has been led in the context of a limited amount of meta-analysis 
for the opioid preparations’ use. Results: The primary research provided data 
of high quality. The average Jadad scale rating for all primary publications was 
equal to 3.43. The individual studies presented the effectiveness of individual drugs. 
However, their variation with respect to the scale assessing either pain intensity 
or diversity of a population makes the presentation of meta-analysis impossible to 
be presented. ConClusions: Oncology pain treatment has been assessed in high 
number of published studies. However due to their heterogeneity the meta-analisis 
methodology is limited to be used.
PSY11
a PiLot StuDY of tHE EffEctivEnESS of tREatmEnt PatiEntS witH 
HEmoPHiLia in ukRainE
Zalis’ka O.1, Mudrak Y.2, Mudrak I.2
1Danylo halytsky Lviv National Medical University, Lviv, Ukraine, 2Vinnyca National Medical 
University after M. Pyrogov, Vinnyca, Ukraine
objeCtives: The incidence is 87% of hemophilia and often leads to disability (90% 
of patients). WHO recommends annual demand of 1 patient of 30 000 IU of factor 
VIII, but in Ukraine with a national program funded an average 5786 IU per year 
(20% of the need). In Ukraine, began production of the domestic drug factor VIII 
“BioKlot A” from 2012. The aim was to determine the effectiveness of substitution 
treatment “BioKlot A” native medicine in the treatment of patients with hemophilia 
A. Methods: In a pilot clinical study examined 168 patients diagnosed with hemo-
philia A severe form of male, aged 18-52 years, who were hospitalized. Experimental 
group received “BioKlot A” control group – “Oktanat” in equal doses of 40 IU / kg / 
day during the first day, 20 IU / kg / day - the next day. All patients were determined 
by the intensity of joint pain, joint swelling index, joint circumference, blood count, 
and others criteria. Results: Within 24 hours after “BioKlot A” (average dose rate 
of 10 000 IU) joint pain significantly decreased after 48 hours - the pain disappeared 
and the joint volume decreased by 14% in 72 hours - the amount of diminished 
joint by 22% and increased range of motion by 28%. Time coagulation by Lee-White 
24 hours decreased from 30 ± 0,2 minute to 19 ± 0,2 minute. In the control group, 
the average dose rate amounted to 10750 IU “Oktanat” and dynamics of clinical 
and hematological data were not significantly different from the experimental 
group. ConClusions: The established similar effectiveness of factor VIII “BioKlot 
A” (Ukraine) and “Oktanat” (Austria) with clinical and laboratory criteria. Production 
of factor VIII preparation in Ukraine has significant socio-economic impact, provid-
ing improved quality of life of patients.
PSY12
How to imPRovE HEaLtH outcomES in tHE tREatmEnt of cHRonic 
mYELoiD LEukEmia
Viriato D.1, Marques A.1, Fonseca M.1, Almeida A.2
1Novartis, Porto Salvo, Portugal, 2Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
objeCtives: Imatinib and nilotinib are two tyrosine kinase inhibitors (TKI) used in 
the treatment of chronic myeloid leukemia (CML). Recent data reveals that patients 
who achieve deep molecular responses may be able to stop TKI, which has impor-
tant clinical and economic implications. The efficacy of nilotinib was compared 
to imatinib in newly diagnosed patients and the proportion of patients achieving 
deep molecular response MR4.5, after 5 years, was 31% for imatinib and 54% for 
nilotinib. The aim of this analysis was to estimate the number of patients remaining 
in TFR with nilotinib compared with imatinib. Methods: According to STIM trial, 
39% of patients remained in complete molecular response after discontinuation 
of imatinib. In the Stop 2G-TKI study, 62.2% remained in undetectable molecular 
residual disease after nilotinib discontinuation. Based on this data, we developed 
an outcomes model to estimate the number of patients remaining in TFR long term 
after consolidated treatment with nilotinib versus imatinib. It was assumed that 
after 5 years of treatment with imatinib or nilotinib, patients with consistent MR4.5 
are eligible to interrupt treatment. After 12 months, patients who maintain sus-
tained undetectable BCR-ABL will remain in TFR. Results: Considering an annual 
CML incidence of 1.33 per 100,000 patients, of which 8% are intolerant to treatment, 
we estimated 128 de novo CML patients eligible for TKI treatment in Portugal per 
year. For this cohort of patients, treatment with nilotinib would result in an addi-
tional 28 patients in TFR when compared with imatinib (43 versus 15). Given the 
number of patients remaining in TFR, overall treatment costs with nilotinib, after 
country multi-center medical chart-review study of AS patients was conducted 
among rheumatologists in UK/France/Germany/Italy/Spain to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30yrs) and patient volume (incl. 
> 5AS biologic patients/month) and recruited from a large panel to be geographi-
cally representative in each country. Eligible patient charts (≥ 3) were randomly 
selected from a sample of prospective patients visiting each center/practice dur-
ing the screening period. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status/outcomes. Patients 
on adalimumab/etanercept monotherapy were analyzed. Results: 329 eligible 
AS patient charts were abstracted; 141 on adalimumab (male: 89%, age: 41.9yrs, 
average months on adalimumab: 29.5, 95% on first biologic) and 102 on etanercept 
(male: 78%, age: 43.2yrs, average months on etanercept: 32.2, 98% on first biologic). 
Top-3 comorbidites (adalimumab vs. etanercept) were dyslipidemia: 6% (range: 0% 
(Germany) -11% (Italy)) vs. 8% (range: 0% (UK/Germany) -15% (Spain)), obesity: 4% 
(range: 0% (Italy) -7% (Germany)) vs. 6% (range: 0% (UK) -11% (France)), and depres-
sion: 6% (range: 0% (Italy/Spain) -15% (UK)) vs. 5% (range: 0% (Germany/Spain) -7% 
(Italy/France)). Among patients with available data, latest lab measures documented 
were (adalimumab vs. etanercept): ESR: 15.1mm/h (range: 11.6 (Germany) - 23.6 
(Italy)) vs. 13.6mm/h (range: 8.0 (Germany) -19.2 (Italy)), CRP: 6.7mg/dl (range: 2.6 
(Spain) -8.9 (France)) vs. 7.3mg/dl (range: 1.9 (Germany) -10.0 (Italy)), rheumatoid 
factor-positive: 6% (range: 0% (Spain) -10% (Germany/Italy)) vs. 10% (range: 0% (UK) 
-19% (Italy)). Latest disease severity measures documented were (adalimumab vs. 
etanercept): Swollen Joint Counts: 0.8 (range: 0.1 (Germany) -1.4 (UK)) vs. 0.5 (range: 
0.3 (France) -0.9 (Italy)), Tender Joint Counts: 1.2 (range: 0.5 (Germany) -1.9 (Italy)) 
vs. 1.1 (range: 0.4 (France) -2.1 (Italy)), HAQ: 1.1 (range: 0.7 (Spain) -1.5 (UK)) vs. 1.3 
(range: 1.0 (France) -3.0 (Germany)). ConClusions: Among AS patients receiving 
adalimumab or etanercept monotherapy, disease severity differed within the EU5, 
with patients on adalimumab, and patients in Italy, having marginally higher burden 
and poorer outcomes. Factors influencing the observed patterns and the impact 
of specific biologic treatments on these observations warrant further scrutiny to 
optimize therapeutic interventions and improve outcomes.
PSY8
a DouBLE-BLinD contRoLLED StuDY of tHE EfficacY anD SafEtY of 
Long-acting amfEPRamonE tREatmEnt in mExican oBESE PatiEntS
Soto Molina H.1, Pizarro Castellanos M.2, Rosado Perez J.3, Rizzoli Cordoba A.2, Fernández 
del Valle C.4, Reyes García J.G.4
1hS estudios Farmacoeconómicos, Mexico city, Mexico, 2hospital Infantil Federico Gomez,  
Distrito Federal, Mexico, 3FeS Zaragoza, Mexico city, Mexico, 4Instituto Politécnico Nacional, 
Mexico city, Mexico
objeCtives: Amfepramone is an anorectic drug used for the short-term treat-
ment of obesity; however, its efficacy and safety in the long-term has been scarcely 
studied. To determine the efficacy and safety of long-acting amfepramone treat-
ment in Mexican adult obese patients by a double blind, randomized and placebo-
controlled clinical trial study. Methods: One hundred and fifty six volunteers 
with a body mass index (BMI) greater than 30 kg/m2 and less than 45 kg/m2 were 
randomized to receive a tablet of 75 mg amfepramone or placebo daily during 6 
months. Primary outcomes were the absolute body weight loss and the percent-
age of patients who achieved at least 5% or 10% weight loss at 3 and 6 months, 
whereas secondary outcomes were the improvement of anthropometric and meta-
bolic parameters. Results: Amfepramone treatment showed a superior efficacy 
to decrease the body weight than placebo at 3 (-4.9 ± 0.25 versus 0.7 ± 0.32 Kg) and 
6 (7.7 ± 0.52 versus 1.1 ± 0.7 Kg) months. In addition, Sixty-four and thirty-four 
patients achieved at least 5% or 10% weight loss, respectively, with amfepramone 
at 6 months, compared with eight and zero patients of placebo. Amfepramone also 
improved BMI and waist circumference, but not waist-hip index (WHI), glucose, 
total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL) and 
triglycerides at 3 and 6 months. Amfepramone produced only mild adverse events 
and they were presented in a greater number than placebo only at 3 months, being 
the main adverse event dry mouth. ConClusions: Data suggest that amfepramone 
is effective and well tolerated in the long-term treatment of Mexican obese patients.
PSY9
comPaRativE EffEctivEnESS StuDY of EnzYmatic REPLacEmEnt 
tHERaPiES in tHE tREatmEnt of gaucHERxS DiSEaSE on aDuLtS
Muciño-Ortega E.1, Mendoza C.F.1, Rubio M.E.2
1Pfizer S.a. de c.V., ciudad de México, Mexico, 2Pfizer S.a. de c.V., Mexico city, Mexico
objeCtives: This study aims to perform a comparative effectiveness study of 
licensed Enzymatic Replacement Therapies (ERT´, taliglucerase, imiglucerase and 
velaglucerase) on the treatment of Gaucher´s disease on adult patients. Methods: 
A systematic review of published clinical trials was performed on three Medical 
databases. Inclusion criteria were randomized, double-blind and phase III clinical 
trials measuring the efficacy of ERT on adult patients. Using meta-analysis method-
ology, the difference in the clinical outputs due the use of a specific ERT in four end-
points was assessed: Hemoglobin concentration increase, platelet count increase, 
Spleen and Liver volume reduction. Since no placebo group is reported in clinical 
trials of orphan drugs, outcomes previous to ERT were considered as control. In this 
study we report the p-value of test for subgroup differences to compare among the 
three alternatives. Results: For the higher dose (60U/kg for the three enzymes), the 
data reported allowed a taliglucerase, velaglucerase and Imiglucerase comparison in 
efficacy measures (except the analysis of imiglucerase in platelet count endpoint). 
Hemoglobin concentration increased a mean of 1.79 g/dL [95% CI 1.08, 2.51; p-value 
for therapy differences= 0.82]. Spleen volume decreased a mean of -5.17 Multiples 
of Normal (MN) [-10.09, -0.25; p-value for therapy differences= 0.90]. ERT showed a 
trend favouring liver volume reduction, -0.28 MN [-0.57, 0.01; p-value for therapy 
differences= 0.80] and increased platelet count, 33.11x109/L [-1.67, 67.89; p-value for 
therapy differences= 0.74]. However, for data limitations, we were unable to perform 
the comparison for the lower dose (taliglucerase and imiglucerase 30U/kg, velagluc-
